BGJ398 (NVP-BGJ398)

BGJ398 (NVP-BGJ398)は、強力で選択的な線維芽細胞成長因子レセプター家族阻害剤で、FGFR1, FGFR2, FGFR3 と FGFR4に作用すると、 IC50がそれぞれ0.9 nM、 1.4 nM、 1 nM と60 nMになる。

価格 在庫  
USD 138 あり
USD 214 あり
USD 340 あり
USD 718 あり
USD 1222 あり

BGJ398 (NVP-BGJ398) 化学構造
分子量: 560.48

高品質保証

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare FGFR Inhibitors
    FGFR製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 BGJ398 (NVP-BGJ398)は、強力で選択的な線維芽細胞成長因子レセプター家族阻害剤で、FGFR1, FGFR2, FGFR3 と FGFR4に作用すると、 IC50がそれぞれ0.9 nM、 1.4 nM、 1 nM と60 nMになる。
ターゲット FGFR1 FGFR2 FGFR3 FGFR4
IC50 0.9 nM 1.4 nM 1 nM 60 nM [1]
In vitro試験 BGJ398 also prevents VEGFR2 with low potency. The IC50 of BGJ398 for inhibiting VEGFR2 is 0.18 μM. BGJ398 suppresses other kinases including ABL, FYN, KIT, LCK, LYN and YES with IC50 of 2.3 μM, 1.9 μM, 0.75 μM, 2.5 μM, 0.3 μM and 1.1 μM, respectively. At the cellular level, BGJ398 inhibits the proliferation of the FGFR1-, FGFR2-Q, and FGFR3-dependent BaF3 cells with IC50 of 2.9 μM, 2.0 μM and 2 μM, respectively. BGJ398 interferes with autophosphorylation on specific tyrosine residues including FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC50 of 4.6 nM, 4.9 nM, 5 nM, 5 nM and 168 nM, respectively. BGJ398 suppresses proliferation of the cancer cells with wild-type (WT) FGFR3 overexpression such as RT112, RT4, SW780 and JMSU1 with IC50 of 5 nM, 30 nM, 32 nM and 15 nM, respectively. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HCC MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoNU0zPTByIH7N MWC0PEBp NH31VmHDqEmFNUC9JFI{PTokgJnucS=> M1nXUVI2Pjh6N{Sz
HCC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHCdHB4OS1{NUCwJI5O MlrQOFghcA>? MmjOTWM2OD1zMUK05qCKdm1? NFHGSYgzPTZ6OEe0Ny=>
HCT116 NXfMR3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\IN2Q1QCCq M2LnNGlEPTB;MzFOwG0> MmTFNlQ2ODN3M{i=
HKH2 NHG5NpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy0PEBp NXnTdVR7UUN3ME20JO69VQ>? NV\hdolZOjR3MEO1N|g>
RKO NVXUT49NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PJUFQ5KGh? MVnJR|UxRTFwMjFOwG0> NYLsWlBMOjR3MEO1N|g>
LS174T M2\TWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW0PEBp NEjsdoxKSzVyPUSg{txO MmPENlQ2ODN3M{i=
HCD9 M4LESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\3dZcxNjVvNTFOwG0> M3vNd|Q5Nzd{IHi= NEf6N2VFVVOR NWn2VJI4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5 M1rQZlI1OTN3OEG2
HCT116 NVHB[VdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV34VYRKOC53LUWg{txO NFjUcZU1QC95MjDo MlPoSG1UVw>? MXvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHl? M1P0NlI1OTN3OEG2
SNU-C1 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnYe4gxNjVvNTFOwG0> Mle1OFgwPzJiaB?= NH;ybnpFVVOR MofNco8h\W[oZXP0 MmTtNlQyOzV6MU[=
MFE280 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwNkOgxtEhOC56MjFOwG0> M{DxZ|I{PDR|OEC1
AN3CA MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml71TWM2OD1zLkCwJOKyKDBwMkCg{txO NH7PfIQzOzR2M{iwOS=>
HEC155 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ZbGlEPTB;ND63OEDDuSBzLkC5JO69VQ>? Ml\pNlM1PDN6MEW=
MFE296 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\6RmlEPTB;Mj64OkDDuSByLkKwJO69VQ>? NGP3NIgzOzR2M{iwOS=>
SPAC1S M33pNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojHTWM2OD1|LkG5JOKyKDBwOUOg{txO MkD6NlM1PDN6MEW=
RL952 M1fkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfkS4tKSzVyPUOuOFEhyrFiMD6yN{DPxE1? MWSyN|Q1OzhyNR?=
EN1 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TCOmlEPTB;ND63OUDDuSByLk[yJO69VQ>? MYGyN|Q1OzhyNR?=
SNGII NWXXSIZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTSdVZ4UUN3ME20MlI6KMLzIECuOVgh|ryP NXflfIRMOjN2NEO4NFU>
ISHIKAWA NXPRepNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXQbHNKSzVyPUWuOFghyrFiMD6wN{DPxE1? NVfHeHZYOjN2NEO4NFU>
HEC1A NXznRmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITZPJpKSzVyPUGwMlAxKMLzIEGuNFAh|ryP NEP0VHEzOzR2M{iwOS=>
KLE MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nSTmlEPTB;Mz6wN{DDuSByLkGxJO69VQ>? M1KxSFI{PDR|OEC1
SNGM NEHtUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTVwMECgxtEhOC52MTFOwG0> M3zre|I{PDR|OEC1
USPC2 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7BcmpRUUN3ME23MlAxKMLzIECuNlEh|ryP NYCyfWEyOjN2NEO4NFU>
EN M3e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnyTWM2OD14LkCzJOKyKDBwM{Gg{txO MkHMNlM1PDN6MEW=
MFE319 NX;GSXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC2NINiUUN3ME21MlM4KMLzIECuNFMh|ryP NWHWUZZ7OjN2NEO4NFU>
EFE184 M3;qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ONWVKSzVyPUiuNFQhyrFiMD62PUDPxE1? M{DpUVI{PDR|OEC1
ECC1 M3nwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LaW2lEPTB;Nj63OEDDuSByLkW5JO69VQ>? NFX5bIIzOzR2M{iwOS=>
HEC1B M4fMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G3cGlEPTB;Nj60OUDDuSByLk[3JO69VQ>? MmmxNlM1PDN6MEW=
USPC1 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;QUGlEPTB;NT63OUDDuSByLkWwJO69VQ>? MWOyN|Q1OzhyNR?=
SPAC1L NY\Z[2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3SPXVKSzVyPUSuPVIhyrFiMD61NEDPxE1? NIHXSFgzOzR2M{iwOS=>

... Click to View More Cell Line Experimental Data

In vivo試験 In this orthotopic xenograft bladder cancer model, BGJ398 induces tumor growth inhibition and stasis after oral administration for 12 consecutive days at the doses of 10 and 30 mg/kg, respectively. Interestingly, the animals that received BGJ398 exhibits either no body weight loss (10 mg/kg) or 10% body weight gain (30 mg/kg), a further indication of efficacy. RT112 tumor-bearing and female Rowett rats receive a single oral administration of the monophosphate salt of BGJ398 at the doses of 4.25 and 8.51 mg/kg. BGJ398 significantly decreases the levels of pFRS2 and pMAPK in a dose-dependent manner. BGJ398 inhibits significantly bFGF-stimulated angiogenesis in a dose-dependent manner. However, BGJ398 does not impair VEGF-induced blood vessel formation. [1]
臨床試験 BGJ398 is currently in a Phase I clinical trial in the treatment of the renal tumors.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Radiometric kinase assay The enzymatic kinase activity is assessed by measuring the phosphorylation of a synthetic substrate by the purified GST-fusion FGFR3-K650E kinase domain, in the presence of radiolabeled ATP. Enzyme activities are measured by mixing 10 μL of a 3-fold concentrated BGJ398 solution or control with 10 μL of the corresponding substrate mixture (peptidic substrate, ATP and [γ33P]ATP). The reactions are initiated by addition of 10 μL of a 3-fold concentrated solution of the enzyme in assay buffer. The final concentrations of the assay components are as following: 10 ng of GST-FGFR3-K650E, 20 mM Tris-HCl, pH 7.5, 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, 250 μg/mL PEG 20000, 2 μg/mL poly(EY) 4:1, 1% DMSO and 0.5 μM ATP (γ-[33P]-ATP 0.1 μCi). The assay is carried out according to the filter binding (FB) method in 96-well plates at room temperature for 10 minutes in a final volume of 30 μL including BGJ398. The enzymatic reactions are stopped by the addition of 20 μL of 125 mM EDTA, and the incorporation of 33P into the polypeptidic substrates is quantified as following: 30 μL of the stopped reaction mixture are transferred onto Immobilon-PVDF membranes previously soaked for 5 minutes with methanol, rinsed with water, soaked for 5 min with 0.5% H3PO4, and mounted on vacuum manifold with disconnected vacuum source. After spotting, vacuum is connected, and each well rinsed with 0.5% H3PO4 (200 μL). Free membranes are removed and ished four times on a shaker with 1% H3PO4 and once with ethanol. Membranes are dried and overlaid with addition of 10 μL/well of a scintillation fluid. The plates are eventually sealed and counted in a microplate scintillation counter. IC50 values are calculated by linear regression analysis of the percentage inhibition of the BGJ398.

細胞アッセイ: [1]

細胞株 Murine BaF3 cell lines
濃度 0 μM-0.1 μM
反応時間 48 hours
実験の流れ Murine BaF3 cell lines, whose proliferation and survival has been rendered IL-3-independent by stable transduction with tyrosine kinases activated either by mutation or fusion with a dimerizing partner, are cultured in RPMI-1640 media supplemented with 10% FBS, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, and Pen/Strep. Cells are passaged twice weekly. BGJ398-mediated inhibition of BaF3 cell proliferation and viability is assessed using a Luciferase bioluminescent assay. Exponentially growing BaF3 or BaF3 Tel-TK cells are seeded into 384-well plates (4250 cells/well) at 50 μL/well using a μFill liquid dispenser in fresh medium. BGJ398 is serially diluted in DMSO and arrayed in a polypropylene 384-well plate. Then 50 nL of BGJ398 are transferred into the plates containing the cells by using the pintool transfer device, and the plates incubated at 37 °C (5% CO2) for 48 hours. Then 25 μL of Bright-Glo are added, and luminescence is quantified using an Analyst-GT. Custom curve-fitting software is used to produce a logistic fit of percent cell viability as a function of the logarithm of inhibitor concentration. The IC50 value is determined as the concentration of BGJ398 needed to reduce cell viability to 50% of a DMSO control.

動物実験: [1]

動物モデル Athymic nude-nu mice bearing parental RT112 cell line
製剤 PEG300/D5W (2:1, v/v)
投薬量 10 mg/kg/qd and 30 mg/kg/qd
投与方法 Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download BGJ398 (NVP-BGJ398) SDF
分子量 560.48
化学式

C26H31Cl2N7O3

CAS No. 872511-34-7
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 1 mg/mL warming (1.78 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)-1-methylurea

文献中の引用 (15)

Frequently Asked Questions

  • Question 1
    If you have any suggestions about the formulation of this compound for a direct oral gavage administration?

    Answer: BGJ398 (S2183) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30 mg/ml as a suspension.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related FGFR 阻害剤

  • CH5183284 (Debio-1347)

    CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.

  • BLU9931

    BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • PD173074

    PD173074は、有力なFGFR1</b> 阻害剤でIC50 が ~25 nM。

  • AZD4547

    AZD4547は、FGFR1、FGFR2とFGFR3を目標としている新しい選択的なFGFR阻害剤で、IC50 がそれぞれ 0.2 nM、 2.5 nM、 1.8 nMです。

    Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.

  • SSR128129E

    SSR128129E is an orally-active and allosteric FGFR inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

  • LY2874455

    LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765)は、0.5nMのIC50による有力で非常に選択的なブラットンのチロシン・キナーゼ(Btk)阻害剤です。

最近チェックしたアイテム

Tags: BGJ398 (NVP-BGJ398)を買う | BGJ398 (NVP-BGJ398)供給者 | BGJ398 (NVP-BGJ398)を購入する | BGJ398 (NVP-BGJ398)費用 | BGJ398 (NVP-BGJ398)生産者 | オーダーBGJ398 (NVP-BGJ398) | BGJ398 (NVP-BGJ398)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID